{"ticker": {"uuid": "c53277d5-2134-440e-85bc-8a69ec9a9425", "symbol": "CYP", "name": "Cynata Therapeutics Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cynata Therapeutics Limited (ASX:CYP): What Progress Is This Stem Cell Therapy Company Making in Its Clinical Programmes?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNSUFmYkszcWU1ak5wVHpFWGJOVDNNc2JlNEtNQkY4ZzdPb3pHU0RlT2JKRzRFcGZuelUyOTc0ZmRVdGRsMjVZSFRNWGJ6X2hsZktYRW9sSkhtcTVtM3drLVdEZjdLWklYMjdQT2Z4THFkckx4NlFwSmFpUDV1UklEdjV6bC1zaDZCdWk4cF8wMXU1cEcycFNTSUlfX3RoWFpXVXBBNDBVY3c2dnJ3YUh4NDE5eHpKWTBFbEE5dHdJSEFYYkg5a1BsUTg0Uzg2eTc4UUNla3pHUVB0ZlZDVnplcFNrZFFsX0t0WnJWc2V2dVg2MEU?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T01:48:00+00:00", "published_display": "10 Jul 2026 01:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cynata Therapeutics Limited \u2013 ASX:CYP", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOUVB3aFZkeEE1Wk1uMHJqSnZCMml2UmVobEJLRnZGMnlpM1VIeE9RYTRIanpBejlaMERsU0Vmc0MzRVREVVNzdmI2bTNFTmJQcHZ4WkVIYVFuS0tiN3hiWGFRb0VrbWJQajQ2TmM0aFpIaTFWNk4tT1BaLUg1cGF5bXN6UXE3NlgxVlJ4cFNyUHc2dnd2LUZQNDNWQkg?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T16:49:18+00:00", "published_display": "09 Jul 2026 16:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX: CYP) Surges 15%\u2014What's Sparking the Market Buzz?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOU0cwWjZycFliOEJTaDNLNFhOc295TV9hb0ZKT0o3ekJrRXVua2V2LVA1U1JrZkNzLXoxdnUtNV9CTHZOcG1kLTlOaV9VcnN4eW4wVEZZTGo5TGRoTXpIRlkzNjZFNXkyVk1KZkRONm4tWW5Pd0N0SXlLN0Z1VllOSkdZUzA0RDlVeHdrUEdKZ2JCN09aeTJGWmdFOEZKVl92dGRzVHpJYUNCdw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-06T10:51:00+00:00", "published_display": "06 Jul 2026 10:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX: CYP): Health Care Cell Therapy Company Overview and Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbHNyeTlybTl4ZC04UGFGcElJSEhWa3JnSS0tbW9seFFjQnJvM2dsTkJsV1Q4eFFpNDZRWExHbGkwNTU3c256RlNKUnVCSG82UllfMHdBSUxQeEEzYXQ5MDJ2elZvVWpvRUVRT3VyajR6dmdEa0hmU2c3ZlhVemw1MWl2U2M4OVNPQXR4MjU2NVFHTFlkTnhMUTYwZ2l5Y19SU0w0VFVsQ3BBbGEzWngzYVI2QWJqbDZacmcyWUxB?oc=5", "source_name": "Kalkine", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics Loses Substantial Shareholder as Bioscience Managers Translation Fund Exits with $373,000 in Share Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPSUtzektQZkk2UFNYSWlYS0FUZVp2TXZBbElNYjlfNUs0YlFuR3BkY2dRN21iQXdBelZvUlR0ZWhvTE1wT1VKU2ZNamhWTEdtQ0R2TGpuRVZwdGpUU3RZRlEyUzNmQV9vcExFSUNkTEtzdG1FNXhwVWc3dEtZdHMybW1hQUxtYTVOaGU0cEllR3JHUlM5bzRxOEhic1BjWTJ5RU5Kb3g5UnRKR05xVktXZFk4alZNelhHM0dHRDVKNjU4eFFSVFlrSHJzVERMMmhNSF9LLXBTcXlsYWNBSzZTZklDdjVpWGZBUm1OT3JWU3NTb1p1NHZz?oc=5", "source_name": "Kalkine", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata\u2019s Cymerus flops in osteoarthritis, GVHD", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPZV9QTEZjNV9falAyaHAyOWVSeUdQczZzUVlNQlZ3QkI1MWZaem5hSGZaT1J3MXFMX3VvYmp6dU8zNHlCZU5JRlhkcWdLYTFWMmlRQ1JWTlVKeUx2NE5oVkRTV1NyMGNiZU14YTFxWGJkX1hrZ2RxLTZCc2t3anhYRFZEekJWd0ZFSmtGYjh3?oc=5", "source_name": "BioWorld News", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX:CYP): ASX Biotech Stock Back in the Spotlight After Osteoarthritis Trial Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZGxOdExuU3pkZFFpMGlyVXB1MS1YTFNkUVhpUVpZYzkxbk5zXzlKNmptaF92M0JIWXFrcldpMEtpeXNZNXNra3FMc2FNb0lKNktBdkJpb1B6aGFIdmlOQzRkaGhFWWZYWE5ocFVBR2tZZHRQVnRWLWpTXzI3SEtOZEhFLVFYeDhaNXJjYmVnZzN1amZERVc3OUItUW5oLWNqQ2hhSWVENGY5YS1MN2hpLXlmd1d6c2QxbmpkMzYxeXAzdXh1d2tuN01vVXpWSWhieVllX1Jn?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Cynata Therapeutics (ASX:CYP) Share Price Dropped Over 90% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTmRsSnVHV2wxVW1la3FEUjJYOEE2QTRuU0VPZGJDN05tN3RldUZzNklQOUhkVVZtVWtrZ2tQbVRURW5wUkV1Rjl1WkpGNU5ZS3JCTk5pcDBTZGEzaFdmTXVvY3BkM05aRHd4UHBUOWVZR1phbnN0WHhKN3dmcXU3dFc1OHZXWWV2cllpUEd6ZkpxT2RPRU1CamtUNmFPbVJLSHZBRXNWNjA?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1GSFVaRFpZS2QwX2FFMWVSSkN2aFpZb0I5MmMtcjBTOHpBOXBNOEZyd3NRcjVvN3FyTUhYSXMtODEzTm9QNzZYWlczRVlIZ0tjQkc5U2FXb3hDalhUUVJLeGNRaV8zQQ?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics Terminates Key Graft Versus Host Disease Trial After Disappointing Phase 2 Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNNmMxdHB2NW1XSi1aLXc2SksyRm9yd3pZSUxFSWRBanZySTkxeHZ2aFktSWlCcFF0SkgySmJuVFdLTGpCOHFjTTNjcm1SdUQ1cmU5WE5ZMnNzdl9LWUFfeWxJbVpraWRHU3FVbFFiQ1NMZ3Nuc3ZkOWZ1T0s4MnpFNjROeXlnT09yYTk5MU1XcldnN0NIazRlbXlUWWpVSXZLYVFEd2dwUnNNTkJPZzZoR3RTNU1OcXA5ZFR4NjZuMG9TVmRUNWhLbGNBTjV5S3RFX2RUTWhSdEhFX0k?oc=5", "source_name": "Sharecafe", "published_at": "2026-06-17T03:21:58+00:00", "published_display": "17 Jun 2026 03:21", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata gains EU endorsement for CYP-001 study plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxORlZlUWVWMVN1MnJ3a05JODdkWGl2RWR1elZYVndpUEM0YTFUeW5Oby0wR05YaHFENnBNTlp0bWMwS2x1ckR4OE5yRzhrUDB3QU0tVUlBSGk0bHVLb2JXUncySzJvRTlxYmp1cllXb2NuWlZMdC1ydVRkdm9CTzB2UUgyd2pScG9kamt4NEZQeFlZSGFZQnpWZUdZcXR5dkFXZmVMWGRTYUEwV1Nnc1MxZXV3VTZ4MmF3ZW85QnFFdmEwUERXRzZQUHVja3ltVjJuMmo4SHp4QUVxcG44YXBlQ1otd1VYSHl0RkQ1ZlI4am5nbDZoVW9vSklBMDk4bFB6R2pPcXpkOFVQeTRHWUtiMzJaczZraUR3dXJQMDhGTHVMVUh4bUVCUms3ONIBsAJBVV95cUxPb3BfMGZCRXpKMlJqb1MtWGdLaGtaMUYxemtDaVVlU0FpbVl5a1BMLWRsX3g5MWNxa1M2eE8zZi1JMElXSkpHM25mQVNGT2EwaGZkYzlXTkZRYlIxc3ZGaWY5QXZVQkY1UU93aVE5NEtWdnNCZlF3NWVicGFSamY1YU9kejVpLXdsVWJRMUhwaDIyVUt1YlhGSU5DRWNNYlJTTGY3RE9nMFdEQmdfbHpLT3hfUFc4Zk5yVy1QLU5rdGlQUEFrNTZxMm9ETTIxUURLNlJnVXF5aktIdF9PM29tc0hpWUk2RGV0LWNuN2I4WG93MGJadFNUcXBUc0JZMmt1MlI1WkpBRFZyekJ6R3FwMV9HaVFVdy1zMnVoV3hJMnIwcmpiOXF3V1RSQVVsNzda?oc=5", "source_name": "The Australian", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX:CYP) Moves Higher Following Regulatory Progress in Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeHpISnRSWVh1YTl2R3RmN2xqR3YwWGljTzIzeVZ1eGMtdUhuSTlZTXZqbFJRb09jcmx1OGNicEVQemVsakNUdW41TGY4aUh0LWc1LXVFdlBxdHlnSXBEWDh6Q2x5OGNWck05SDNKOGRRX0F5T1REdGlxUWExcHFHdlBWRGJvQnB3U1FFZU5mX1ZRNldhcU9xVV9fWUFnSkdLNi1xajRMSTRUR1JqZEtQLXg1cHJKcU5wcnc?oc=5", "source_name": "Kalkine", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Small-Cap Biotech Sentiment Pressuring Cynata Therapeutics (ASX:CYP)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUXRQZnBtRVp0UlhfUjg3ZjBkUTJMWlg4OFQtaWtUYUREQm50dVpLdjF2OU9xVFhmZk8tN05JMEN3cmRadDNua1U5ejk5SmFaaDlmOC1IMmxvRFh2QWhCc3h0R19xckptTy1ucEJOZ24xZGZVREhPSEMwbG9Ld3VYX2JVdU4zZTBfMFJYQk5XMWQ5S01uVDd3QTlvSWp2T0FIcWJObHVSc3p2U2s?oc=5", "source_name": "Kalkine", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata prepares for pivotal trial readouts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOa2tFbFdnaVd3S0pKX1RudFM5RldPdVdrdkM3WlFZbGVJNk4tRUNnRTdBdGc1TFBMZ2U2RVNTWDZ6UThRUlBwak5OSDc4VG5KQzFEZm02ZFViOFJNa1FvWi1MQUxxMFd6NGZCZ2g5MzBqb1B0QndyaW14RUVzTUtsQQ?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata positioned for 2026 trial readouts after doing the leg work in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYWltSTM3MWxHeXdwNDUzWVdGb016S0VFbEowYTk3eGR0ZDY5ejV3S2J4VHYyTXV0R1VUTkd2Q1BzSVhVQVIzSWNSTmVOR3ZGSUJSM2xsWFRhTUs5T1pxQl9BTDFpcThGTkg3b0QwcVZscTRKbThZVGxONFhxTVZJUXBUN1N3WmlaLUtDdDhjN0ZrQk5aUkg1VTI5aWdrR1o4RVd0WTNNeWNBVFE?oc=5", "source_name": "Stockhead", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Final patient visit complete in Cynata\u2019s phase III trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Cynata Therapeutics Ltd (ASX:CYP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE1XZ1kxcXRDeUV4aEl2eVRPSGFVaHZQNHVUdVAyRzhxTkhUY1FtTEQ1aVhFWjQyNzZhMUhqQkVJTm0yMU00MVkzbk1aOGFQYmxK?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T15:10:13+00:00", "published_display": "30 Oct 2025 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Cynata Therapeutics Limited (ASX:CYP) Turn A Profit?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX:CYP) is making steady progress: Interview with Dr. Kilian Kelly", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTFBmTWpOeTU2OVF4RUl1RUJ2ME9iOHhLM0I0ZVdQTzJ5dnA4VmM2ejF6UjlneE9QdHZiOWxQUFJfZFRZQXhTb19Rczd0OGgzYy0yZEdQbWV2dDBGb3R6X2FKVFR0NXJ1bHZLeGQ2NmpjajBtUQ?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-10-13T05:45:01+00:00", "published_display": "13 Oct 2025 05:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Can We Expect A Profit From Cynata Therapeutics Limited (ASX:CYP)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOU0w4YVJkRjdFT3RoWGRGZjVqYlpORGV1MXl5NDRmS2RqWnZLdEhjcXYwSnA0SHVFMW0xX1VPRFVtY3hYMDlnUEpfZkpyTzZ3OWF4ajBsVjZMMUpKV3loWk9OQldpVVlOVnBVaVFUMC1vUnJZMUdXeUhUTjVkTVU1RUw1Nl9QbG82TENjeW1ITjE?oc=5", "source_name": "Market source", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-29T07:00:00+00:00", "published_display": "29 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Introduces Critical Innovation into MSC Manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFBobUtuTGJ4UVNfQmdRSkNjQ0RJaHZxZmdJSmNUTXpYMlMyTURIZXQwWGdrb1RrNzlwWnVyUmxPR2Iwazk5QkY4UXFEajBjbF9nT0FVdHo0UzktenE4dk5n0gFkQVVfeXFMTXFVZEE4akZyRmNENG5YWkFxWlB1WjgwQTFoYlRlcXRnNmJ3X20xZExwWkdWN1JacldjNm1QdVFOTU9SZTVZb2xMZzNKUUdvQWJkbzdLQ3pXbFdyd1g1NDJnYWY5SQ?oc=5", "source_name": "BioInformant", "published_at": "2024-12-06T08:00:00+00:00", "published_display": "06 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Cynata\u2019s Cymerus\u2122 Platform Be A Tool for Fighting the Pandemic?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOaHVoTElfRnpzT1BaQnE1M1hUVDZSMUpsTjdLVUpieFdVaDZzRHpQZ0hsV19WZVUzUnUxNVgzUFM0cEoyLVZpRVdVbUFGVFEyRFB4SHMzaE5SN2tfcVlYQktKMkx5VVRnWmFyNTZKZm1sNWN5ZllLZFlxWWdSUk5mQm11aTZMbEnSAYwBQVVfeXFMT1ZUSTBUX3dNQjdZV2RlNGJUbmJMTmkxMW1RZ01ocnp2Nkk1U3NaMmVtSUJZVURSVzhqcGZhTE4ySkEwZmZEZXhSUXJSSVBWdmhETnNVdkpuNlB1cURhcFdWVWJBSjRlWF9hYS1TTlBncHYtLXBJRGZ2SnhEa044UU81Z3pMeFZFMGs5dHo?oc=5", "source_name": "BioInformant", "published_at": "2024-08-22T07:00:00+00:00", "published_display": "22 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cynata Therapeutics Limited (ASX:CYP): What Progress Is This Stem Cell Therapy Company Making in Its Clinical Programmes?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNSUFmYkszcWU1ak5wVHpFWGJOVDNNc2JlNEtNQkY4ZzdPb3pHU0RlT2JKRzRFcGZuelUyOTc0ZmRVdGRsMjVZSFRNWGJ6X2hsZktYRW9sSkhtcTVtM3drLVdEZjdLWklYMjdQT2Z4THFkckx4NlFwSmFpUDV1UklEdjV6bC1zaDZCdWk4cF8wMXU1cEcycFNTSUlfX3RoWFpXVXBBNDBVY3c2dnJ3YUh4NDE5eHpKWTBFbEE5dHdJSEFYYkg5a1BsUTg0Uzg2eTc4UUNla3pHUVB0ZlZDVnplcFNrZFFsX0t0WnJWc2V2dVg2MEU?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T01:48:00+00:00", "published_display": "10 Jul 2026 01:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cynata Therapeutics Limited \u2013 ASX:CYP", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOUVB3aFZkeEE1Wk1uMHJqSnZCMml2UmVobEJLRnZGMnlpM1VIeE9RYTRIanpBejlaMERsU0Vmc0MzRVREVVNzdmI2bTNFTmJQcHZ4WkVIYVFuS0tiN3hiWGFRb0VrbWJQajQ2TmM0aFpIaTFWNk4tT1BaLUg1cGF5bXN6UXE3NlgxVlJ4cFNyUHc2dnd2LUZQNDNWQkg?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T16:49:18+00:00", "published_display": "09 Jul 2026 16:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX: CYP) Surges 15%\u2014What's Sparking the Market Buzz?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOU0cwWjZycFliOEJTaDNLNFhOc295TV9hb0ZKT0o3ekJrRXVua2V2LVA1U1JrZkNzLXoxdnUtNV9CTHZOcG1kLTlOaV9VcnN4eW4wVEZZTGo5TGRoTXpIRlkzNjZFNXkyVk1KZkRONm4tWW5Pd0N0SXlLN0Z1VllOSkdZUzA0RDlVeHdrUEdKZ2JCN09aeTJGWmdFOEZKVl92dGRzVHpJYUNCdw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-06T10:51:00+00:00", "published_display": "06 Jul 2026 10:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX: CYP): Health Care Cell Therapy Company Overview and Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbHNyeTlybTl4ZC04UGFGcElJSEhWa3JnSS0tbW9seFFjQnJvM2dsTkJsV1Q4eFFpNDZRWExHbGkwNTU3c256RlNKUnVCSG82UllfMHdBSUxQeEEzYXQ5MDJ2elZvVWpvRUVRT3VyajR6dmdEa0hmU2c3ZlhVemw1MWl2U2M4OVNPQXR4MjU2NVFHTFlkTnhMUTYwZ2l5Y19SU0w0VFVsQ3BBbGEzWngzYVI2QWJqbDZacmcyWUxB?oc=5", "source_name": "Kalkine", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics Loses Substantial Shareholder as Bioscience Managers Translation Fund Exits with $373,000 in Share Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPSUtzektQZkk2UFNYSWlYS0FUZVp2TXZBbElNYjlfNUs0YlFuR3BkY2dRN21iQXdBelZvUlR0ZWhvTE1wT1VKU2ZNamhWTEdtQ0R2TGpuRVZwdGpUU3RZRlEyUzNmQV9vcExFSUNkTEtzdG1FNXhwVWc3dEtZdHMybW1hQUxtYTVOaGU0cEllR3JHUlM5bzRxOEhic1BjWTJ5RU5Kb3g5UnRKR05xVktXZFk4alZNelhHM0dHRDVKNjU4eFFSVFlrSHJzVERMMmhNSF9LLXBTcXlsYWNBSzZTZklDdjVpWGZBUm1OT3JWU3NTb1p1NHZz?oc=5", "source_name": "Kalkine", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata\u2019s Cymerus flops in osteoarthritis, GVHD", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPZV9QTEZjNV9falAyaHAyOWVSeUdQczZzUVlNQlZ3QkI1MWZaem5hSGZaT1J3MXFMX3VvYmp6dU8zNHlCZU5JRlhkcWdLYTFWMmlRQ1JWTlVKeUx2NE5oVkRTV1NyMGNiZU14YTFxWGJkX1hrZ2RxLTZCc2t3anhYRFZEekJWd0ZFSmtGYjh3?oc=5", "source_name": "BioWorld News", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX:CYP): ASX Biotech Stock Back in the Spotlight After Osteoarthritis Trial Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZGxOdExuU3pkZFFpMGlyVXB1MS1YTFNkUVhpUVpZYzkxbk5zXzlKNmptaF92M0JIWXFrcldpMEtpeXNZNXNra3FMc2FNb0lKNktBdkJpb1B6aGFIdmlOQzRkaGhFWWZYWE5ocFVBR2tZZHRQVnRWLWpTXzI3SEtOZEhFLVFYeDhaNXJjYmVnZzN1amZERVc3OUItUW5oLWNqQ2hhSWVENGY5YS1MN2hpLXlmd1d6c2QxbmpkMzYxeXAzdXh1d2tuN01vVXpWSWhieVllX1Jn?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Cynata Therapeutics (ASX:CYP) Share Price Dropped Over 90% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTmRsSnVHV2wxVW1la3FEUjJYOEE2QTRuU0VPZGJDN05tN3RldUZzNklQOUhkVVZtVWtrZ2tQbVRURW5wUkV1Rjl1WkpGNU5ZS3JCTk5pcDBTZGEzaFdmTXVvY3BkM05aRHd4UHBUOWVZR1phbnN0WHhKN3dmcXU3dFc1OHZXWWV2cllpUEd6ZkpxT2RPRU1CamtUNmFPbVJLSHZBRXNWNjA?oc=5", "source_name": "Kalkine", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1GSFVaRFpZS2QwX2FFMWVSSkN2aFpZb0I5MmMtcjBTOHpBOXBNOEZyd3NRcjVvN3FyTUhYSXMtODEzTm9QNzZYWlczRVlIZ0tjQkc5U2FXb3hDalhUUVJLeGNRaV8zQQ?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics Terminates Key Graft Versus Host Disease Trial After Disappointing Phase 2 Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNNmMxdHB2NW1XSi1aLXc2SksyRm9yd3pZSUxFSWRBanZySTkxeHZ2aFktSWlCcFF0SkgySmJuVFdLTGpCOHFjTTNjcm1SdUQ1cmU5WE5ZMnNzdl9LWUFfeWxJbVpraWRHU3FVbFFiQ1NMZ3Nuc3ZkOWZ1T0s4MnpFNjROeXlnT09yYTk5MU1XcldnN0NIazRlbXlUWWpVSXZLYVFEd2dwUnNNTkJPZzZoR3RTNU1OcXA5ZFR4NjZuMG9TVmRUNWhLbGNBTjV5S3RFX2RUTWhSdEhFX0k?oc=5", "source_name": "Sharecafe", "published_at": "2026-06-17T03:21:58+00:00", "published_display": "17 Jun 2026 03:21", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata gains EU endorsement for CYP-001 study plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX:CYP) Moves Higher Following Regulatory Progress in Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeHpISnRSWVh1YTl2R3RmN2xqR3YwWGljTzIzeVZ1eGMtdUhuSTlZTXZqbFJRb09jcmx1OGNicEVQemVsakNUdW41TGY4aUh0LWc1LXVFdlBxdHlnSXBEWDh6Q2x5OGNWck05SDNKOGRRX0F5T1REdGlxUWExcHFHdlBWRGJvQnB3U1FFZU5mX1ZRNldhcU9xVV9fWUFnSkdLNi1xajRMSTRUR1JqZEtQLXg1cHJKcU5wcnc?oc=5", "source_name": "Kalkine", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Small-Cap Biotech Sentiment Pressuring Cynata Therapeutics (ASX:CYP)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUXRQZnBtRVp0UlhfUjg3ZjBkUTJMWlg4OFQtaWtUYUREQm50dVpLdjF2OU9xVFhmZk8tN05JMEN3cmRadDNua1U5ejk5SmFaaDlmOC1IMmxvRFh2QWhCc3h0R19xckptTy1ucEJOZ24xZGZVREhPSEMwbG9Ld3VYX2JVdU4zZTBfMFJYQk5XMWQ5S01uVDd3QTlvSWp2T0FIcWJObHVSc3p2U2s?oc=5", "source_name": "Kalkine", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata prepares for pivotal trial readouts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOa2tFbFdnaVd3S0pKX1RudFM5RldPdVdrdkM3WlFZbGVJNk4tRUNnRTdBdGc1TFBMZ2U2RVNTWDZ6UThRUlBwak5OSDc4VG5KQzFEZm02ZFViOFJNa1FvWi1MQUxxMFd6NGZCZ2g5MzBqb1B0QndyaW14RUVzTUtsQQ?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata positioned for 2026 trial readouts after doing the leg work in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYWltSTM3MWxHeXdwNDUzWVdGb016S0VFbEowYTk3eGR0ZDY5ejV3S2J4VHYyTXV0R1VUTkd2Q1BzSVhVQVIzSWNSTmVOR3ZGSUJSM2xsWFRhTUs5T1pxQl9BTDFpcThGTkg3b0QwcVZscTRKbThZVGxONFhxTVZJUXBUN1N3WmlaLUtDdDhjN0ZrQk5aUkg1VTI5aWdrR1o4RVd0WTNNeWNBVFE?oc=5", "source_name": "Stockhead", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Final patient visit complete in Cynata\u2019s phase III trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxQVDNXNnNnTEc5S0cwNUhMN0YyRGV1WTVNYWZwM21WdjQ0S21OaHRqclBiV0gtOTUwUTFYaGppaTRlVVl6ekxpdG5KTEotU25rUTR0OFdRdGxXblFrWkpYSzhqTzJ0UjhrY3VsZWRwdzVBaGdZRl93ZEtrZkU1QUZEMWR2aVJmbkdNOXdoMzJQeHdEbEFWSHV3TEtWZ3FJcmN6YVdQb0x5ZTdPcXZ3c2FnQ21ST3oxWVBTRUdqaENIRS1pZFdTSGMxbHJaUlBsSm9scFlpMWJyLW4xSTFWRm9YVXpuMnBQWE93aVQzblRYX0VtVWdnT1NZVHFFQW9UUjJYa1U3QXBwSmV3SkVKbEYyRlhJQlPSAZoCQVVfeXFMUDB0VDdlX0lRazh5akJZdllVWVA4aG1OZGVUNXNsOUIyUE9TYm5rS0toWENMR3oxWl9Gd1pqQ3ZraFF2ZHJVcnpkOUVMQnJQZUxUUWtROE9qRmQzTEV4cEhJcDc0T2xMbTVkNlE0RVFqT21QbVpEUHdORTN4NGM0a0d6NmdjVmdrVkdyWlh5bmVLUWhwcXgtaFBRaWhjNTFPM3JKTEV3UUdVVGM4a3JETmZPX3B4TTd0dThFZUthRlZrbzZUQjE4dmJxYTByWWFIQXB1Yk85V2lDaGhUQUZ0b3IyQ1lwSmozbllPWDBwSTlWNC1rZVVSY2lvajBJTTdGZlNraEZrbTlOUmFvT05xXzNLSXZxaHRZUU53?oc=5", "source_name": "The Australian", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Cynata Therapeutics Ltd (ASX:CYP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE1XZ1kxcXRDeUV4aEl2eVRPSGFVaHZQNHVUdVAyRzhxTkhUY1FtTEQ1aVhFWjQyNzZhMUhqQkVJTm0yMU00MVkzbk1aOGFQYmxK?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T15:10:13+00:00", "published_display": "30 Oct 2025 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Cynata Therapeutics Limited (ASX:CYP) Turn A Profit?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Therapeutics (ASX:CYP) is making steady progress: Interview with Dr. Kilian Kelly", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTFBmTWpOeTU2OVF4RUl1RUJ2ME9iOHhLM0I0ZVdQTzJ5dnA4VmM2ejF6UjlneE9QdHZiOWxQUFJfZFRZQXhTb19Rczd0OGgzYy0yZEdQbWV2dDBGb3R6X2FKVFR0NXJ1bHZLeGQ2NmpjajBtUQ?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-10-13T05:45:01+00:00", "published_display": "13 Oct 2025 05:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Can We Expect A Profit From Cynata Therapeutics Limited (ASX:CYP)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOU0w4YVJkRjdFT3RoWGRGZjVqYlpORGV1MXl5NDRmS2RqWnZLdEhjcXYwSnA0SHVFMW0xX1VPRFVtY3hYMDlnUEpfZkpyTzZ3OWF4ajBsVjZMMUpKV3loWk9OQldpVVlOVnBVaVFUMC1vUnJZMUdXeUhUTjVkTVU1RUw1Nl9QbG82TENjeW1ITjE?oc=5", "source_name": "Market source", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-29T07:00:00+00:00", "published_display": "29 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cynata Introduces Critical Innovation into MSC Manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFBobUtuTGJ4UVNfQmdRSkNjQ0RJaHZxZmdJSmNUTXpYMlMyTURIZXQwWGdrb1RrNzlwWnVyUmxPR2Iwazk5QkY4UXFEajBjbF9nT0FVdHo0UzktenE4dk5n0gFkQVVfeXFMTXFVZEE4akZyRmNENG5YWkFxWlB1WjgwQTFoYlRlcXRnNmJ3X20xZExwWkdWN1JacldjNm1QdVFOTU9SZTVZb2xMZzNKUUdvQWJkbzdLQ3pXbFdyd1g1NDJnYWY5SQ?oc=5", "source_name": "BioInformant", "published_at": "2024-12-06T08:00:00+00:00", "published_display": "06 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Cynata\u2019s Cymerus\u2122 Platform Be A Tool for Fighting the Pandemic?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOaHVoTElfRnpzT1BaQnE1M1hUVDZSMUpsTjdLVUpieFdVaDZzRHpQZ0hsV19WZVUzUnUxNVgzUFM0cEoyLVZpRVdVbUFGVFEyRFB4SHMzaE5SN2tfcVlYQktKMkx5VVRnWmFyNTZKZm1sNWN5ZllLZFlxWWdSUk5mQm11aTZMbEnSAYwBQVVfeXFMT1ZUSTBUX3dNQjdZV2RlNGJUbmJMTmkxMW1RZ01ocnp2Nkk1U3NaMmVtSUJZVURSVzhqcGZhTE4ySkEwZmZEZXhSUXJSSVBWdmhETnNVdkpuNlB1cURhcFdWVWJBSjRlWF9hYS1TTlBncHYtLXBJRGZ2SnhEa044UU81Z3pMeFZFMGs5dHo?oc=5", "source_name": "BioInformant", "published_at": "2024-08-22T07:00:00+00:00", "published_display": "22 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 83, "total_relevant": 24, "sentiment_summary": {"positive": 6, "negative": 2, "neutral": 16, "score": 53, "total": 24, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 0.01, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": -95.0, "twelve_week_move": -96.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.286314, "market_dynamics_buy_signal": false, "relative_strength": -94.922564, "fair_value_gap": -93.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.6553, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, -95.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 8}, {"label": "Stocks Down Under", "count": 3}, {"label": "The Australian", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "BioInformant", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "BioWorld News", "count": 1}, {"label": "Sharecafe", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 24}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 18}, {"label": "Earnings", "count": 4}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "24", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, -95.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Cynata Therapeutics Limited (ASX:CYP): What Progress Is This Stem Cell Therapy Company Making in Its Clinical Programmes?"}], "updated_at": "2026-07-17T07:34:23.248013+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}